



# ArmaGen

Technologies, Inc.

*Enabling Biotechnology for  
the Brain*



**Blood-Brain Barrier  
Molecular Trojan Horse  
Technology**



**Re-engineering a  
recombinant protein by  
fusion to ArmaGen's  
molecular Trojan horse  
creates a new chemical  
entity that penetrates  
the brain**

**ArmaGen Technologies, Inc.**  
914 Colorado Ave.  
Santa Monica, CA 90401  
Ph: (310) 917-1275  
Fax: (310) 917-1276  
[www.armagen.com](http://www.armagen.com)

## Corporate Fact Sheet

ArmaGen Technologies, Inc. is a privately-held biotechnology company developing therapeutic products for the central nervous system.

### **Molecular Trojan Horse Platform Technology**

ArmaGen re-engineers recombinant proteins to enable transport across the human blood-brain barrier (BBB) and penetration into the brain. With ArmaGen's molecular Trojan horse technology, a new fusion protein is created wherein the protein therapeutic is fused to the Trojan horse, a genetically engineered monoclonal antibody that crosses the human BBB via an endogenous peptide transport system—see adjacent scan of primate brain after intravenous AGT-181 injection.

### **CNS Therapeutic Products in Development**

**AGT-110**, decoy receptor for stroke that crosses the BBB

**AGT-160**, anti-amyloid monoclonal antibody drug for Alzheimer's disease that crosses the BBB

**AGT-181**, a lysosomal enzyme for Hurler's syndrome that penetrates the brain

**AGT-185**, an organophosphatase for organophosphate toxicity that is active in the CNS

**AGT-190**, a neurotrophin for stroke and Parkinson's disease that penetrates the brain

**AGT-3**, a Trojan horse-avidin fusion protein that binds biotinylated drugs for intravenous siRNA delivery to brain

### **Company Highlights**

Raised \$15 million to date.

Strong IP position on platform technology and all therapeutic products in development.

Lead therapeutic presently in cGMP manufacturing; Phase 0 GLP toxicology in primates completed.

Projected IND filing second quarter, 2010.

World leader in technology of brain drug targeting.

### **Contact Information:**

**BUSINESS DEVELOPMENT:** Paul Lee, [plee@armagen.com](mailto:plee@armagen.com)